Skip to main content

Advertisement

SpringerLink
Log in

Diffusivity changes in bevacizumab-responding and -refractory meningioma

  • Letter to the Editor
  • Published:
Neuroradiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Kaley T, Barani I, Chamberlain M et al (2014) Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-Oncology 16:829–840

    Article  PubMed  PubMed Central  Google Scholar 

  2. Furtner J, Schöpf V, Seystahl K et al (2016) Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro-Oncology 18:401–407

    Article  PubMed  Google Scholar 

  3. Ellingson BM, Malkin MG, Rand SD et al (2010) Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 31:538–548

    Article  PubMed  PubMed Central  Google Scholar 

  4. Pope WB, Mirsadraei L, Lai A et al (2012) Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. Am J Neuroradiol 33:1059–1064

    Article  CAS  PubMed  Google Scholar 

  5. Auf G, Jabouille A, Guérit S et al (2010) Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. Proc Natl Acad Sci U S A 31:15553–15558

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology and Brain Tumor Center, Cantonal Hospital, 5001, Aarau, Switzerland

    Ulrich Roelcke

  2. Department of Neuroradiology, Cantonal Hospital, 5001, Aarau, Switzerland

    Jatta Berberat & Luca Remonda

  3. Department of Medical Oncology, Cantonal Hospital, 5001, Aarau, Switzerland

    Christoph Mamot

Authors
  1. Ulrich Roelcke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jatta Berberat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christoph Mamot
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luca Remonda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Roelcke.

Ethics declarations

Funding

No funding was received for this study.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Statement of informed consent was not applicable since the patient was deceased at the time of data analysis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roelcke, U., Berberat, J., Mamot, C. et al. Diffusivity changes in bevacizumab-responding and -refractory meningioma. Neuroradiology 59, 1059–1061 (2017). https://doi.org/10.1007/s00234-017-1923-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00234-017-1923-y

Search

Navigation